Cell Therapy Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapy Type (Autologous, Allogenic), By Therapeutic Area (Oncology, Cardiovascular Diseases, Musculoskeletal Disorders, Dermatology), By Region & Competition, 2020-2030F

Market Overview

Global Cell Therapy Market was valued at USD 6.30 Billion in 2024 and is anticipated to project formidable growth in the forecast period with a CAGR of 12.01% through 2030. In the realm of modern medicine, the convergence of science and innovation has given rise to transformative treatments that were once considered science fiction. One such groundbreaking advancement is cell therapy, a cutting-edge medical approach that harnesses the power of living cells to treat a range of diseases and conditions. The global cell therapy market is rapidly expanding, offering new hope for patients and creating a paradigm shift in the way healthcare is delivered. Cell therapy involves the transplantation or manipulation of living cells into a patient's body to stimulate the repair, regeneration, or replacement of damaged or diseased tissues. These cells can be sourced from the patient's own body (autologous) or from a donor (allogeneic). The therapeutic potential of cell therapy lies in its ability to target the root causes of various diseases at a cellular level, unlike traditional treatments that often focus on symptom management. The global cell therapy market has gained substantial momentum in recent years due to its promising outcomes and a growing understanding of cellular biology.

The market encompasses various therapeutic areas, including oncology, cardiovascular diseases, neurological disorders, musculoskeletal conditions, and autoimmune disorders. Cancer treatment, in particular, has seen significant advancements with the development of chimeric antigen receptor (CAR) T-cell therapies that reprogram the patient's immune cells to target and destroy cancer cells. The market is also supported by increased investment from pharmaceutical companies, research institutions, and venture capital firms. Governments around the world are recognizing the potential of cell therapy and are providing regulatory support, streamlined approval processes, and funding to expedite its development and commercialization. Despite the challenges, the global cell therapy market is poised for substantial growth. Ongoing research into cellular biology, advances in gene editing techniques (such as CRISPR-Cas9), and innovative approaches to manufacturing are expected to drive progress. The convergence of cell therapy with other fields like genomics and artificial intelligence holds the potential to further refine treatment approaches, making them even more personalized and effective. Moreover, the expansion of the market beyond traditional applications to areas like wound healing, diabetes, and rare genetic disorders could unlock new avenues for growth. As the body of evidence supporting the efficacy of cell therapies continues to grow, more stakeholders, including healthcare providers, insurers, and patients, are likely to embrace these treatments as a viable option.

Key Market Drivers

Increasing Prevalence of Chronic and Degenerative Diseases

The rising prevalence of chronic and degenerative diseases is one of the primary factors fueling the expansion of the Global Cell Therapy Market. In 2020, an estimated 523 million individuals globally were affected by cardiovascular diseases (CVDs), with approximately 19 million fatalities attributed to these conditions. This accounted for nearly 32% of all global deaths and reflected an 18.7% increase in absolute mortality compared to 2010. As conventional treatment methods often fail to provide long-term solutions for these conditions, cell therapy is emerging as a breakthrough alternative, offering regenerative and disease-modifying potential.  In 2021, noncommunicable diseases (NCDs) were responsible for at least 43 million deaths worldwide, accounting for 75% of all non-pandemic-related fatalities. Alarmingly, 18 million of these deaths occurred in individuals under the age of 70, with 82% of premature fatalities concentrated in low- and middle-income countries. This growing burden highlights a significant unmet medical need for more effective, accessible, and preventive healthcare solutions, particularly in regions with limited resources. Chronic and degenerative diseases such as cancer, cardiovascular diseases, autoimmune disorders, diabetes, and neurodegenerative conditions pose a significant global healthcare burden. Traditional treatment options, including pharmaceuticals and surgical interventions, often provide only symptom relief rather than disease reversal or regeneration. Cell therapy, particularly stem cell and immune cell-based treatments, offers a transformative approach by promoting tissue regeneration, reducing inflammation, and potentially curing previously untreatable diseases. As the global population ages and chronic disease prevalence rises, demand for more effective, long-term solutions is accelerating investment and adoption of cell therapies.

In 2020, cancer was responsible for approximately 10 million deaths worldwide, accounting for nearly one in six fatalities. The most prevalent cancer types include breast, lung, colorectal, and prostate cancers. Notably, around one-third of cancer-related deaths are linked to modifiable risk factors, such as tobacco use, obesity, alcohol consumption, poor nutrition, and physical inactivity. Cancer remains a leading cause of mortality worldwide, with traditional treatments such as chemotherapy, radiation, and targeted therapies having limitations in efficacy and long-term remission. CAR-T cell therapy and other immune-based cell therapies have demonstrated high efficacy in hematologic malignancies and are now being explored for solid tumors. The success of CAR-T therapies like Kymriah (Novartis) and Yescarta (Gilead Sciences) has paved the way for increased investments in next-generation cell-based immunotherapies. Ongoing research into allogeneic (off-the-shelf) CAR-T and natural killer (NK) cell therapies is further expanding the oncology cell therapy market, creating new commercial opportunities.

Rising Investments and Strategic Collaborations

The Global Cell Therapy Market is witnessing accelerated growth, largely fueled by rising investments and strategic collaborations across the healthcare and biotechnology sectors. With increasing financial backing from pharmaceutical companies, venture capital firms, government initiatives, and private equity investors, as well as partnerships between biotech startups, academic institutions, and large corporations, the market is experiencing significant advancements in research, development, and commercialization. 

In 2024, investment in the cell and gene therapy sector surged to USD15.2 billion, marking a 30% year-over-year increase. The industry has witnessed significant momentum in public financings, with Insmed securing USD650 million in May 2024 and Kyverna raising USD319 million through its IPO to advance its autoimmune cell therapy initiatives. This surge in capital reflects growing investor confidence and strong market demand for next-generation therapeutic solutions, driving accelerated development and commercialization within the sector. The cell therapy industry has become a key focus area for investors, with a substantial increase in venture capital and private equity funding directed toward biotech startups and mid-sized firms specializing in regenerative medicine and immunotherapies. Early-stage biotech firms are securing significant funding rounds to support R&D, clinical trials, and manufacturing scale-up. Major investors are betting on cell therapy’s potential for breakthrough treatments, particularly in oncology, rare diseases, and autoimmune disorders. This influx of capital is enabling companies to accelerate clinical development, regulatory submissions, and commercialization efforts, ensuring faster market entry for innovative therapies.

Pharmaceutical companies are increasingly forming strategic partnerships with emerging biotech firms to strengthen their cell therapy pipelines and gain a competitive edge. Access advanced research, cutting-edge technologies, and novel cell therapy platforms. Share financial risks and leverage combined expertise in drug development, manufacturing, and regulatory pathways. Accelerate clinical trial progression and optimize commercialization strategies. Bristol Myers Squibb partnered with Century Therapeutics to develop iPSC-derived allogeneic cell therapies, expanding its immuno-oncology portfolio. Such collaborations allow big pharma companies to diversify their portfolios, while biotech startups benefit from financial support, regulatory guidance, and global distribution networks.

Download Free Sample Report

Key Market Challenges

Complex Regulatory Landscape

One of the foremost challenges in the cell therapy market is navigating the complex and evolving regulatory landscape. Unlike traditional pharmaceuticals, which are based on small molecules, cell therapies involve live cells that interact with the patient's body. This dynamic nature raises unique safety and efficacy concerns, leading to intricate regulatory requirements. Ensuring compliance with these regulations can be time-consuming and resource-intensive, potentially delaying the development and approval process.

Safety and Efficacy Concerns

Cell therapies often involve modifying or transplanting cells into patients, which can introduce unforeseen risks. Ensuring the safety of patients is paramount, as unintended side effects or complications could have serious consequences. Additionally, demonstrating the efficacy of cell therapies requires rigorous clinical trials and long-term follow-up, which can be logistically challenging and resource-intensive.

Standardization and Scalability

Manufacturing cell therapies at scale while maintaining consistent quality is a significant hurdle. Unlike traditional drugs, which can be mass-produced with relative ease, cell therapies involve working with living cells that are sensitive to environmental conditions. Developing standardized manufacturing processes and techniques that can be reliably replicated is essential to ensure consistent outcomes for patients.

Key Market Trends

Technological Advancements

The field of medical science is undergoing a transformative phase, with remarkable breakthroughs occurring at an unprecedented pace. Among these groundbreaking advancements, cell therapy stands out as a beacon of hope, promising revolutionary treatments for a multitude of diseases that were once considered untreatable. As technological innovations continue to accelerate, the cell therapy market is experiencing a rapid expansion, offering new avenues for treating a diverse range of medical conditions. Stem cells, with their unique ability to differentiate into various cell types, have captured the attention of researchers and clinicians alike. Advances in stem cell isolation, manipulation, and differentiation techniques have enabled the development of personalized therapies for conditions ranging from neurodegenerative disorders to cardiovascular diseases. The emergence of precise gene editing tools like CRISPR-Cas9 has revolutionized the field of cell therapy. This technology allows scientists to modify a cell's genetic material, correcting mutations or enhancing desired traits before transplantation. Gene-edited cells offer improved therapeutic potential and reduced risks of immune rejection. Immunotherapies harness the body's immune system to target and destroy disease-causing cells. Chimeric Antigen Receptor (CAR) T-cell therapy, a form of immunotherapy, has shown remarkable success in treating certain types of leukemia and lymphoma. Ongoing research aims to expand the applications of CAR-T therapy to solid tumors and other diseases. Microfluidic devices and automated systems have streamlined the production and manipulation of cells for therapy. These technologies enhance scalability, consistency, and quality control, ensuring that cell-based treatments can be manufactured in large quantities without compromising safety and efficacy. As technology continues to evolve, the cell therapy market is projected to experience exponential growth. The convergence of these technological advancements has propelled the development of novel and effective therapies for conditions that were once considered incurable. From autoimmune diseases to degenerative disorders, the spectrum of diseases that can potentially be addressed through cell therapy continues to expand. However, it's important to note that along with the potential benefits, challenges remain. Safety concerns, regulatory hurdles, and the complexities of manufacturing consistent and viable cell therapies on a large scale are among the issues that need to be addressed to fully realize the potential of this field.

Segmental Insights

Therapeutic Area Insights

Based on the category of Therapeutics Area, Oncology segment emerges as the fastest growing segment in the Global Cell Therapy market. Cancer is a complex and often challenging disease to treat. Traditional treatment methods like chemotherapy, radiation therapy, and surgery have limitations, and there is a constant need for more effective and targeted therapies. Cell therapies, especially those involving immune cells like CAR-T cells (chimeric antigen receptor T cells), have shown promising results in treating certain types of cancer that are resistant to other treatments. Immunotherapy, which includes cell therapies like CAR-T cell therapy, harnesses the body's immune system to recognize and attack cancer cells. This approach has transformed cancer treatment by providing potentially curative options for patients who had limited or no treatment options previously. CAR-T cell therapies, for instance, involve modifying a patient's T cells to recognize and target cancer cells, leading to improved outcomes in certain leukemia and lymphoma cases.

Download Free Sample Report

Regional Insights

Based on region, North America region was emerged as the largest market in the Global Cell Therapy Market, this is due to United States, has a long history of investing in biomedical research and innovation. This has led to the development of advanced technologies and methodologies for cell therapy, including stem cell research and regenerative medicine. North America boasts a robust biotechnology and pharmaceutical industry, with numerous established companies and startups focusing on cell therapy research and development. These companies often have the financial resources and expertise to advance their products to the market. Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA), have provided clear pathways for the approval and commercialization of cell therapies. This clarity has encouraged companies to invest in research and development in the region. North America also has a well-developed healthcare infrastructure, including a vast network of hospitals and research institutions. This infrastructure supports the clinical trials and testing necessary for the approval and adoption of new cell therapies.

Recent Developments

• In March 2025, The FDA has granted approval to revakinagene taroretcel-lwey (Encelto), an allogeneic encapsulated cell-based gene therapy developed for the treatment of idiopathic macular telangiectasia type 2 (MacTel) in adults. This regulatory milestone establishes Encelto as the first and only authorized treatment for this rare neurodegenerative retinal disorder, which leads to progressive and irreversible vision loss. The approval positions Encelto as a groundbreaking advancement in ophthalmic therapeutics, addressing a critical unmet need in the market.
• In January 2025, The FDA has approved Ryoncil, marking a significant milestone as the first mesenchymal stromal cell (MSC) therapy to receive regulatory clearance. Additionally, Ryoncil is the first off-the-shelf allogeneic cell therapy product to enter the market, setting a new precedent in regenerative medicine. This approval underscores the therapeutic potential of MSCs and positions Ryoncil as a commercially scalable solution in the advanced cell therapy landscape.
• In December 2024, The FDA has approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged two months and older. This landmark approval establishes Ryoncil as the first MSC therapy to receive FDA authorization, positioning it as a critical advancement in addressing a severe and life-threatening complication of stem cell transplantation.
• In August 2024, Artiva Biotherapeutics, Inc., a clinical-stage company specializing in off-the-shelf allogeneic natural killer (NK) cell therapies, announced that the FDA has granted Fast Track designation to its lead candidate, AlloNK® (AB-101), for lupus nephritis (LN) in combination with rituximab or obinutuzumab. This designation follows the FDA’s prior clearance of an Investigational New Drug (IND) application for AlloNK in combination with rituximab, marking the first IND approval for an allogeneic NK cell therapy in autoimmune disease. AlloNK is a cryopreserved, non-genetically modified NK cell therapy designed to enhance B-cell-targeting monoclonal antibodies, driving more effective B-cell depletion and reinforcing its potential as a next-generation treatment in autoimmune disorders.
• In March 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval applies to patients who have undergone at least two prior lines of treatment, including a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor. The decision reinforces Breyanzi’s potential as an advanced, personalized cell therapy solution in the evolving landscape of hematologic malignancies.
• In August 2023, Astellas Pharma and Poseida Therapeutics revealed a strategic investment, aimed at providing additional backing for the advancement of cancer cell therapies.

Key Market Players

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• JCR Pharmaceuticals Co., Ltd.
• Tego Science
• Atara Biotherapeutics
• Takeda Pharmaceutical Company Limited
• Bluebird Bio, Inc.
• Dendreon Corp.

Report Scope:

In this report, the Global Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell Therapy Market, By Therapy Type:

o   Autologous

o   Allogenic

• Cell Therapy Market, By Therapeutics Area:

o   Oncology

o   Cardiovascular Diseases

o   Musculoskeletal Disorders

o   Dermatology

• Cell Therapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Therapy Market.

Available Customizations:

Global Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Middle East & Africa Cell Therapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com